Damien Giacchero, Constanza Ramacciotti, Jean Philippe Arnault, Maryse Brassard, Eric Baudin, Laurent Maksimovic, Christine Mateus, Gorana Tomasic, Janine Wechsler, Martin Schlumberger, Caroline Robert
{"title":"与多激酶抑制剂vandetanib相关的皮肤毒性效应的新光谱。","authors":"Damien Giacchero, Constanza Ramacciotti, Jean Philippe Arnault, Maryse Brassard, Eric Baudin, Laurent Maksimovic, Christine Mateus, Gorana Tomasic, Janine Wechsler, Martin Schlumberger, Caroline Robert","doi":"10.1001/2013.jamadermatol.192","DOIUrl":null,"url":null,"abstract":"S kin manifestations are among the most frequent adverse effects of targeted therapies. Hyperkeratosis and hand-foot skin reaction are observed with most raf and vascular endothelial growth factor (VEGF) inhibitors, whereas folliculitis is a hallmark of epidermal growth factor receptor (EGFR) blocking agents. Vandetanib (Zactima, ZD6474; AstraZeneca) is a multikinase inhibitor that targets EGFR, VEGF receptors 1, 2, and 3 and the RET (rearranged during transfection) receptor.","PeriodicalId":8175,"journal":{"name":"Archives of dermatology","volume":"148 12","pages":"1418-20"},"PeriodicalIF":0.0000,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.192","citationCount":"45","resultStr":"{\"title\":\"A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.\",\"authors\":\"Damien Giacchero, Constanza Ramacciotti, Jean Philippe Arnault, Maryse Brassard, Eric Baudin, Laurent Maksimovic, Christine Mateus, Gorana Tomasic, Janine Wechsler, Martin Schlumberger, Caroline Robert\",\"doi\":\"10.1001/2013.jamadermatol.192\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"S kin manifestations are among the most frequent adverse effects of targeted therapies. Hyperkeratosis and hand-foot skin reaction are observed with most raf and vascular endothelial growth factor (VEGF) inhibitors, whereas folliculitis is a hallmark of epidermal growth factor receptor (EGFR) blocking agents. Vandetanib (Zactima, ZD6474; AstraZeneca) is a multikinase inhibitor that targets EGFR, VEGF receptors 1, 2, and 3 and the RET (rearranged during transfection) receptor.\",\"PeriodicalId\":8175,\"journal\":{\"name\":\"Archives of dermatology\",\"volume\":\"148 12\",\"pages\":\"1418-20\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1001/2013.jamadermatol.192\",\"citationCount\":\"45\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1001/2013.jamadermatol.192\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/2013.jamadermatol.192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.
S kin manifestations are among the most frequent adverse effects of targeted therapies. Hyperkeratosis and hand-foot skin reaction are observed with most raf and vascular endothelial growth factor (VEGF) inhibitors, whereas folliculitis is a hallmark of epidermal growth factor receptor (EGFR) blocking agents. Vandetanib (Zactima, ZD6474; AstraZeneca) is a multikinase inhibitor that targets EGFR, VEGF receptors 1, 2, and 3 and the RET (rearranged during transfection) receptor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
